Cognition Therapeutics shares rise 1.82% after-hours following positive clinical data presentations by Stoke Therapeutics and Biogen.

Cognition Therapeutics, Inc. rose 1.82% in after-hours trading. The company's stock price increase may be attributed to the positive news from Stoke Therapeutics and Biogen, which announced new clinical data from studies of zorevunersen at the 36th International Epilepsy Congress. The data demonstrated the potential for disease modification with durable seizure reductions and improvements in cognition and behavior on top of standard anti-seizure medicines.